FIG. 6.

SodCII is not release by polymyxin B or CRAMP in a constitutive PmrA background. (A) Wild-type (left) and pmrA(Con) (right) strains were treated with the indicated concentration of polymyxin B (PB) or CRAMP. In each case, a whole-cell extract (W) was compared to the supernatant from an equivalent number of cells after treatment. Proteins in each sample were separated by SDS-PAGE and subjected to immunoblot analysis with anti-SodCII antibody. The strains used were JS926 and JS927. (B) β-Galactosidase activity in strains containing pmrI-lacZ or sodCII-lacZ fusion in wild-type or pmrA(Con) background, grown overnight in LB. PmrA does not control the transcription of sodCII. The strains used were JS928, JS929, JS906, and JS930.